Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

3.783 +0.083 (+2.23%)
Streaming Delayed Price Updated: 11:08 AM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Shareholder Rights Law Firm Robbins LLP Reminds AGEN Stockholders with Large Losses They Should Obtain Counsel to Seek Lead Plaintiff Status in the Agenus Inc. Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, New Fortress, and ZoomInfo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
AGEN Class Action Notice: Robbins LLP Reminds Agenus Inc. Stockholders of Pending AGEN Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
News headline image
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
ROSEN, A LEADING LAW FIRM, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, and ZoomInfo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults ↗
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The... 
Via Benzinga
News headline image
Agenus Inc. Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the AGEN Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Agenus, and ZoomInfo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
From Agenus Inc.
Via Business Wire
News headline image
AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
AGENUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Agenus Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Agenus Inc.
From Robbins LLP
Via GlobeNewswire
News headline image
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Rosen Law Firm Urges Agenus Inc. (NASDAQ: AGEN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
AGENUS INC. (NASDAQ: AGEN) INVESTOR ALERT: Investors With Large Losses in Agenus Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Participate in September Investor Conferences
From Agenus Inc.
Via Business Wire
News headline image
Agenus (AGEN) Q2 2024 Earnings Call Transcript ↗
AGEN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AGEN Stock Earnings: Agenus Misses EPS, Misses Revenue for Q2 2024 ↗
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Agenus Reports Second Quarter 2024 Operational and Financial Results
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Appointment of Tom Harrison to Board of Directors
From Agenus Inc.
Via Business Wire
News headline image
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
From Agenus Inc.
Via Business Wire
News headline image
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus ↗
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy... 
Via Benzinga
News headline image
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
News headline image
Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity ↗
Agenus faces a setback as the FDA advises against accelerated approval for its immunotherapy combination, botensilimab and balstilimab, for relapsed/refractory microsatellite-stable colorectal cancer.... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.